Contact The Gross Law Firm by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc.(SRPT)

Core Points - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the company's gene therapy product, ELEVIDYS [1] - The class period for the lawsuit is from June 22, 2023, to June 24, 2025, during which significant safety risks and adverse events associated with ELEVIDYS were allegedly not disclosed [1] - Shareholders are encouraged to register for participation in the class action by the deadline of August 25, 2025, to potentially be appointed as lead plaintiffs [1] Allegations - The complaint alleges that Sarepta Therapeutics made materially false and misleading statements about ELEVIDYS, including the failure to disclose safety risks and inadequate trial protocols [1] - It is claimed that the severity of adverse events from ELEVIDYS treatment could lead to the halting of trials and increased regulatory scrutiny, impacting the therapy's approval status [1] - The allegations suggest that the defendants lacked a reasonable basis for their positive statements regarding the therapy [1] Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are advised to register for the class action, which includes enrollment in a portfolio monitoring system for case updates [1] - There is no cost or obligation for shareholders to participate in the case [1]